320 related articles for article (PubMed ID: 27496680)
1. Safety and efficacy of thalidomide in patients with POEMS syndrome: a multicentre, randomised, double-blind, placebo-controlled trial.
Misawa S; Sato Y; Katayama K; Nagashima K; Aoyagi R; Sekiguchi Y; Sobue G; Koike H; Yabe I; Sasaki H; Watanabe O; Takashima H; Nishizawa M; Kawachi I; Kusunoki S; Mitsui Y; Kikuchi S; Nakashima I; Ikeda S; Kohara N; Kanda T; Kira J; Hanaoka H; Kuwabara S;
Lancet Neurol; 2016 Oct; 15(11):1129-37. PubMed ID: 27496680
[TBL] [Abstract][Full Text] [Related]
2. Japanese POEMS syndrome with Thalidomide (J-POST) Trial: study protocol for a phase II/III multicentre, randomised, double-blind, placebo-controlled trial.
Katayama K; Misawa S; Sato Y; Sobue G; Yabe I; Watanabe O; Nishizawa M; Kusunoki S; Kikuchi S; Nakashima I; Ikeda S; Kohara N; Kanda T; Kira J; Hanaoka H; Kuwabara S;
BMJ Open; 2015 Jan; 5(1):e007330. PubMed ID: 25573527
[TBL] [Abstract][Full Text] [Related]
3. Thalidomide reduces serum VEGF levels and improves peripheral neuropathy in POEMS syndrome.
Kuwabara S; Misawa S; Kanai K; Sawai S; Hattori T; Nishimura M; Nakaseko C
J Neurol Neurosurg Psychiatry; 2008 Nov; 79(11):1255-7. PubMed ID: 18469028
[TBL] [Abstract][Full Text] [Related]
4. Lenalidomide Treatment for Thalidomide-refractory POEMS Syndrome: A Prospective Single-arm Clinical Trial.
Suichi T; Misawa S; Nagashima K; Sato Y; Iwai Y; Katayama K; Sekiguchi Y; Shibuya K; Amino H; Suzuki YI; Tsuneyama A; Nakamura K; Kuwabara S
Intern Med; 2020 May; 59(9):1149-1153. PubMed ID: 32009091
[TBL] [Abstract][Full Text] [Related]
5. Vascular endothelial growth factor as a predictive marker for POEMS syndrome treatment response: retrospective cohort study.
Misawa S; Sato Y; Katayama K; Hanaoka H; Sawai S; Beppu M; Nomura F; Shibuya K; Sekiguchi Y; Iwai Y; Watanabe K; Amino H; Ohwada C; Takeuchi M; Sakaida E; Nakaseko C; Kuwabara S
BMJ Open; 2015 Nov; 5(11):e009157. PubMed ID: 26560063
[TBL] [Abstract][Full Text] [Related]
6. Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study.
Cavo M; Tacchetti P; Patriarca F; Petrucci MT; Pantani L; Galli M; Di Raimondo F; Crippa C; Zamagni E; Palumbo A; Offidani M; Corradini P; Narni F; Spadano A; Pescosta N; Deliliers GL; Ledda A; Cellini C; Caravita T; Tosi P; Baccarani M;
Lancet; 2010 Dec; 376(9758):2075-85. PubMed ID: 21146205
[TBL] [Abstract][Full Text] [Related]
7. A prospective phase II study of low dose lenalidomide plus dexamethasone in patients with newly diagnosed polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes (POEMS) syndrome.
Li J; Huang XF; Cai QQ; Wang C; Cai H; Zhao H; Zhang L; Cao XX; Gale RP; Zhou DB
Am J Hematol; 2018 Jun; 93(6):803-809. PubMed ID: 29603764
[TBL] [Abstract][Full Text] [Related]
8. Lenalidomide and dexamethasone in patients with POEMS syndrome: results of a prospective, open-label trial.
Nozza A; Terenghi F; Gallia F; Adami F; Briani C; Merlini G; Giordano L; Santoro A; Nobile-Orazio E
Br J Haematol; 2017 Dec; 179(5):748-755. PubMed ID: 29048107
[TBL] [Abstract][Full Text] [Related]
9. Multiple angiogenetic factors are upregulated in POEMS syndrome.
Yamada Y; Sawai S; Misawa S; Kanai K; Shibuya K; Mori M; Moriya J; Sogawa K; Yamamoto H; Beppu M; Taniguchi J; Nakaseko C; Nomura F; Kuwabara S
Ann Hematol; 2013 Jan; 92(2):245-8. PubMed ID: 23053181
[TBL] [Abstract][Full Text] [Related]
10. Successful treatment with bortezomib and thalidomide for POEMS syndrome associated with multicentric mixed-type Castleman's disease.
Wang X; Ye S; Xiong C; Gao J; Xiao C; Xing X
Jpn J Clin Oncol; 2011 Oct; 41(10):1221-4. PubMed ID: 21890654
[TBL] [Abstract][Full Text] [Related]
11. Lenalidomide plus dexamethasone versus observation in patients with high-risk smouldering multiple myeloma (QuiRedex): long-term follow-up of a randomised, controlled, phase 3 trial.
Mateos MV; Hernández MT; Giraldo P; de la Rubia J; de Arriba F; Corral LL; Rosiñol L; Paiva B; Palomera L; Bargay J; Oriol A; Prosper F; López J; Arguiñano JM; Quintana N; García JL; Bladé J; Lahuerta JJ; Miguel JS
Lancet Oncol; 2016 Aug; 17(8):1127-1136. PubMed ID: 27402145
[TBL] [Abstract][Full Text] [Related]
12. Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders (RIN-1 study): a multicentre, randomised, double-blind, placebo-controlled trial.
Tahara M; Oeda T; Okada K; Kiriyama T; Ochi K; Maruyama H; Fukaura H; Nomura K; Shimizu Y; Mori M; Nakashima I; Misu T; Umemura A; Yamamoto K; Sawada H
Lancet Neurol; 2020 Apr; 19(4):298-306. PubMed ID: 32199095
[TBL] [Abstract][Full Text] [Related]
13. Pachymeningeal involvement in POEMS syndrome: dramatic cerebral MRI improvement after lenalidomide therapy.
Briani C; Manara R; Lessi F; Citton V; Zambello R; Adami F
Am J Hematol; 2012 May; 87(5):539-41. PubMed ID: 22389216
[TBL] [Abstract][Full Text] [Related]
14. Correlation of changes in serum level of VEGF and peripapillary retinal thickness in patients with POEMS syndrome.
Yokouchi H; Baba T; Misawa S; Oshitari T; Kuwabara S; Yamamoto S
Br J Ophthalmol; 2020 Jan; 104(1):33-38. PubMed ID: 30914422
[TBL] [Abstract][Full Text] [Related]
15. Eltrombopag for children with chronic immune thrombocytopenia (PETIT2): a randomised, multicentre, placebo-controlled trial.
Grainger JD; Locatelli F; Chotsampancharoen T; Donyush E; Pongtanakul B; Komvilaisak P; Sosothikul D; Drelichman G; Sirachainan N; Holzhauer S; Lebedev V; Lemons R; Pospisilova D; Ramenghi U; Bussel JB; Bakshi KK; Iyengar M; Chan GW; Chagin KD; Theodore D; Marcello LM; Bailey CK
Lancet; 2015 Oct; 386(10004):1649-58. PubMed ID: 26231455
[TBL] [Abstract][Full Text] [Related]
16. [Treatment of POEMS syndrome with lenalidomide and dexamethasone].
Goto A; Iyama S; Sugama Y; Yoshida M; Ibata S; Tatekoshi A; Fujita C; Kikuchi S; Ikeda H; Murase K; Takada K; Kato J; Kobune M
Rinsho Ketsueki; 2019; 60(4):308-313. PubMed ID: 31068561
[TBL] [Abstract][Full Text] [Related]
17. Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial.
Mateos MV; Oriol A; Martínez-López J; Gutiérrez N; Teruel AI; de Paz R; García-Laraña J; Bengoechea E; Martín A; Mediavilla JD; Palomera L; de Arriba F; González Y; Hernández JM; Sureda A; Bello JL; Bargay J; Peñalver FJ; Ribera JM; Martín-Mateos ML; García-Sanz R; Cibeira MT; Ramos ML; Vidriales MB; Paiva B; Montalbán MA; Lahuerta JJ; Bladé J; Miguel JF
Lancet Oncol; 2010 Oct; 11(10):934-41. PubMed ID: 20739218
[TBL] [Abstract][Full Text] [Related]
18. Docetaxel and prednisone with or without lenalidomide in chemotherapy-naive patients with metastatic castration-resistant prostate cancer (MAINSAIL): a randomised, double-blind, placebo-controlled phase 3 trial.
Petrylak DP; Vogelzang NJ; Budnik N; Wiechno PJ; Sternberg CN; Doner K; Bellmunt J; Burke JM; de Olza MO; Choudhury A; Gschwend JE; Kopyltsov E; Flechon A; Van As N; Houede N; Barton D; Fandi A; Jungnelius U; Li S; de Wit R; Fizazi K
Lancet Oncol; 2015 Apr; 16(4):417-25. PubMed ID: 25743937
[TBL] [Abstract][Full Text] [Related]
19. Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial.
Gay F; Oliva S; Petrucci MT; Conticello C; Catalano L; Corradini P; Siniscalchi A; Magarotto V; Pour L; Carella A; Malfitano A; Petrò D; Evangelista A; Spada S; Pescosta N; Omedè P; Campbell P; Liberati AM; Offidani M; Ria R; Pulini S; Patriarca F; Hajek R; Spencer A; Boccadoro M; Palumbo A
Lancet Oncol; 2015 Dec; 16(16):1617-29. PubMed ID: 26596670
[TBL] [Abstract][Full Text] [Related]
20. Intravenous aflibercept for treatment of recurrent symptomatic malignant ascites in patients with advanced ovarian cancer: a phase 2, randomised, double-blind, placebo-controlled study.
Gotlieb WH; Amant F; Advani S; Goswami C; Hirte H; Provencher D; Somani N; Yamada SD; Tamby JF; Vergote I
Lancet Oncol; 2012 Feb; 13(2):154-62. PubMed ID: 22192729
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
